[Federal Register Volume 76, Number 222 (Thursday, November 17, 2011)]
[Page 71351]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-29726]



National Institutes of Health

Prospective Grant of Exclusive License: Development of 
Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic 
Encephalopathy in Humans.

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.


SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the invention embodied in U.S. 
Patent 6,630,507, entitled ``Cannabinoids as antioxidants and 
neuroprotectants'' and PCT Application Serial No. PCT/US99/08769 and 
foreign equivalents thereof, entitled ``Cannabinoids as antioxidants 
and neuroprotectants'' [HHS Ref. No. E-287-1997/2] to KannaLife 
Sciences Inc., which has offices in New York, U.S. This patent and its 
foreign counterparts have been assigned to the Government of the United 
States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to:

    The development and sale of cannabinoid(s) and cannabidiol(s) 
based therapeutics as antioxidants and neuroprotectants for use and 
delivery in humans, for the treatment of hepatic encephalopathy, as 
claimed in the Licensed Patent Rights.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
December 19, 2011 will be considered.

ADDRESSES: Requests for copy of the patent, inquiries, comments, and 
other materials relating to the contemplated exclusive license should 
be directed to: Betty B. Tong, Ph.D., Senior Licensing and Patenting 
Manager, Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 594-6565; Facsimile: (301) 402-0220; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: The technology describes pharmaceutical 
compositions of cannabinoids that are useful as tissue protectants, 
such as neuroprotectants and cardioprotectants. The cannabinoids 
compounds may be used, for example, in the treatment of acute ischemic 
neurological insults or chronic neurodegenerative diseases. 
Nonpsychoactive cannabinoids, such as Cannabidiol (CBD), are 
particularly advantageous since they avoid toxicity that is encountered 
with psychoactive cannabinoids at high doses.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
thirty (30) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: November 10, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-29726 Filed 11-16-11; 8:45 am]